A rare complication of imatinib mesylate therapy: drug-induced pneumonitis
The use of imatinib mesylate (Glivec®) (Novartis Pharma AG, Switzerland) that is the drug of choice in treating patients with chronic myeloid leukemia (CML) has increased 7-year survival and improved the prognosis of the disease. The drug is generally tolerated well; the proportion of patients in wh...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2010-02-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | https://ter-arkhiv.ru/0040-3660/article/view/30558 |
| _version_ | 1828498333084155904 |
|---|---|
| author | Ol'ga Veniaminovna Stakhina A G Turkina I E Kostina Yu B Kochkareva O V Stakhina A G Turkina I E Kostina Yu B Kochkareva |
| author_facet | Ol'ga Veniaminovna Stakhina A G Turkina I E Kostina Yu B Kochkareva O V Stakhina A G Turkina I E Kostina Yu B Kochkareva |
| author_sort | Ol'ga Veniaminovna Stakhina |
| collection | DOAJ |
| description | The use of imatinib mesylate (Glivec®) (Novartis Pharma AG, Switzerland) that is the drug of choice in treating patients with chronic myeloid leukemia (CML) has increased 7-year survival and improved the prognosis of the disease. The drug is generally tolerated well; the proportion of patients in whom imatinib treatment results in the development of toxic complications is small. Drug-induced interstitial pneumonitis associated with imatinib therapy is a rare complication that requires timely differential diagnosis, discontinuation of an inductor (imatinib), and altered further treatment policy. |
| first_indexed | 2024-12-11T13:05:16Z |
| format | Article |
| id | doaj.art-3aaf491b1fc343ebaddd82327cdb074e |
| institution | Directory Open Access Journal |
| issn | 0040-3660 2309-5342 |
| language | Russian |
| last_indexed | 2024-12-11T13:05:16Z |
| publishDate | 2010-02-01 |
| publisher | "Consilium Medicum" Publishing house |
| record_format | Article |
| series | Терапевтический архив |
| spelling | doaj.art-3aaf491b1fc343ebaddd82327cdb074e2022-12-22T01:06:21Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422010-02-01822596127585A rare complication of imatinib mesylate therapy: drug-induced pneumonitisOl'ga Veniaminovna StakhinaA G TurkinaI E KostinaYu B KochkarevaO V StakhinaA G TurkinaI E KostinaYu B KochkarevaThe use of imatinib mesylate (Glivec®) (Novartis Pharma AG, Switzerland) that is the drug of choice in treating patients with chronic myeloid leukemia (CML) has increased 7-year survival and improved the prognosis of the disease. The drug is generally tolerated well; the proportion of patients in whom imatinib treatment results in the development of toxic complications is small. Drug-induced interstitial pneumonitis associated with imatinib therapy is a rare complication that requires timely differential diagnosis, discontinuation of an inductor (imatinib), and altered further treatment policy.https://ter-arkhiv.ru/0040-3660/article/view/30558chronic myeloid leukemiadrug-induced pneumonitisinterstitial pneumoniaimatinib mesylate |
| spellingShingle | Ol'ga Veniaminovna Stakhina A G Turkina I E Kostina Yu B Kochkareva O V Stakhina A G Turkina I E Kostina Yu B Kochkareva A rare complication of imatinib mesylate therapy: drug-induced pneumonitis Терапевтический архив chronic myeloid leukemia drug-induced pneumonitis interstitial pneumonia imatinib mesylate |
| title | A rare complication of imatinib mesylate therapy: drug-induced pneumonitis |
| title_full | A rare complication of imatinib mesylate therapy: drug-induced pneumonitis |
| title_fullStr | A rare complication of imatinib mesylate therapy: drug-induced pneumonitis |
| title_full_unstemmed | A rare complication of imatinib mesylate therapy: drug-induced pneumonitis |
| title_short | A rare complication of imatinib mesylate therapy: drug-induced pneumonitis |
| title_sort | rare complication of imatinib mesylate therapy drug induced pneumonitis |
| topic | chronic myeloid leukemia drug-induced pneumonitis interstitial pneumonia imatinib mesylate |
| url | https://ter-arkhiv.ru/0040-3660/article/view/30558 |
| work_keys_str_mv | AT olgaveniaminovnastakhina ararecomplicationofimatinibmesylatetherapydruginducedpneumonitis AT agturkina ararecomplicationofimatinibmesylatetherapydruginducedpneumonitis AT iekostina ararecomplicationofimatinibmesylatetherapydruginducedpneumonitis AT yubkochkareva ararecomplicationofimatinibmesylatetherapydruginducedpneumonitis AT ovstakhina ararecomplicationofimatinibmesylatetherapydruginducedpneumonitis AT agturkina ararecomplicationofimatinibmesylatetherapydruginducedpneumonitis AT iekostina ararecomplicationofimatinibmesylatetherapydruginducedpneumonitis AT yubkochkareva ararecomplicationofimatinibmesylatetherapydruginducedpneumonitis AT olgaveniaminovnastakhina rarecomplicationofimatinibmesylatetherapydruginducedpneumonitis AT agturkina rarecomplicationofimatinibmesylatetherapydruginducedpneumonitis AT iekostina rarecomplicationofimatinibmesylatetherapydruginducedpneumonitis AT yubkochkareva rarecomplicationofimatinibmesylatetherapydruginducedpneumonitis AT ovstakhina rarecomplicationofimatinibmesylatetherapydruginducedpneumonitis AT agturkina rarecomplicationofimatinibmesylatetherapydruginducedpneumonitis AT iekostina rarecomplicationofimatinibmesylatetherapydruginducedpneumonitis AT yubkochkareva rarecomplicationofimatinibmesylatetherapydruginducedpneumonitis |